Lizhi Chen1, Yunyun Yang1,2, Xuebin Wang1, Chenyu Wang2, Weiwei Lin3, Zheng Jiao2,4, Zhuo Wang1. 1. Department of Pharmacy, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, People's Republic of China. 2. Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, People's Republic of China. 3. Department of Pharmacology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, People's Republic of China. 4. Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China.
Abstract
PURPOSE: In this study, we aimed to establish a tacrolimus population pharmacokinetic model and better understand the drug-drug interaction between Wuzhi capsule and tacrolimus in Chinese renal transplant recipients. PATIENTS AND METHODS: We performed a population pharmacokinetic analysis using a non-linear mixed-effects model to determine the suitable Wuzhi capsule dose in combination with tacrolimus. Data on 1378 tacrolimus steady-state concentrations were obtained from 142 patients who received kidney transplant in Changhai Hospital and Huashan Hospital. Demographic characteristics, laboratory tests, genetic polymorphisms, and co-medications were evaluated. RESULTS: The one-compartment model best described data. Our final model identified creatinine clearance rate, hematocrit, Wuzhi capsule dose, CYP3A5*3 genetic polymorphisms, and tacrolimus daily dose as significant covariates for tacrolimus clearance, with the value of 14.4 L h-1, and the between-subject variability (BSV) was 25.4%. The Wuzhi capsule showed a dose-dependent effect on tacrolimus pharmacokinetics, demonstrating a stronger inhibitory effect than inductive effect. CONCLUSION: Our model can accurately describe population pharmacokinetics of tacrolimus when combined with different doses of Wuzhi capsule. Additionally, this model can be used for individualizing tacrolimus dose following kidney transplantation.
PURPOSE: In this study, we aimed to establish a tacrolimus population pharmacokinetic model and better understand the drug-drug interaction between Wuzhi capsule and tacrolimus in Chinese renal transplant recipients. PATIENTS AND METHODS: We performed a population pharmacokinetic analysis using a non-linear mixed-effects model to determine the suitable Wuzhi capsule dose in combination with tacrolimus. Data on 1378 tacrolimus steady-state concentrations were obtained from 142 patients who received kidney transplant in Changhai Hospital and Huashan Hospital. Demographic characteristics, laboratory tests, genetic polymorphisms, and co-medications were evaluated. RESULTS: The one-compartment model best described data. Our final model identified creatinine clearance rate, hematocrit, Wuzhi capsule dose, CYP3A5*3 genetic polymorphisms, and tacrolimus daily dose as significant covariates for tacrolimus clearance, with the value of 14.4 L h-1, and the between-subject variability (BSV) was 25.4%. The Wuzhi capsule showed a dose-dependent effect on tacrolimus pharmacokinetics, demonstrating a stronger inhibitory effect than inductive effect. CONCLUSION: Our model can accurately describe population pharmacokinetics of tacrolimus when combined with different doses of Wuzhi capsule. Additionally, this model can be used for individualizing tacrolimus dose following kidney transplantation.
Authors: J T Tang; L M Andrews; T van Gelder; Y Y Shi; R H N van Schaik; L L Wang; D A Hesselink Journal: Expert Opin Drug Metab Toxicol Date: 2016-04-07 Impact factor: 4.481
Authors: Ina Koch; Regina Weil; Renzo Wolbold; Jürgen Brockmöller; Elisabeth Hustert; Oliver Burk; Andreas Nuessler; Peter Neuhaus; Michel Eichelbaum; Ulrich Zanger; Leszek Wojnowski Journal: Drug Metab Dispos Date: 2002-10 Impact factor: 3.922
Authors: Rogier R Press; Bart A Ploeger; Jan den Hartigh; Tahar van der Straaten; Johannes van Pelt; Meindert Danhof; Johan W de Fijter; Henk-Jan Guchelaar Journal: Ther Drug Monit Date: 2009-04 Impact factor: 3.681